https://www.brighteon.com/3fad7413-9369-4fe7-b61c-cdd55616f270
Ivermectin
Not
approved by the FDA and not recommended by the Panel for the treatment
of COVID-19. Currently under investigation in clinical trials. |
|---|
Dose for COVID-19 in Clinical Trials: - IVM 200–600 μg/kg PO as a single dose or a once-daily dose for up to 5 days
| - Dizziness
- Pruritis
- GI effects (e.g., nausea, diarrhea)
- Neurological
AEs have been reported when IVM has been used to treat parasitic
diseases, but it is not clear whether these AEs were caused by IVM or
the underlying conditions.
| - Monitor for potential AEs.
| - Minor CYP3A4 substrate
- P-gp substrate
| - Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.4
- A list of clinical trials is available: Ivermectin
|
Es wurde am Menschen getestet und hat auch wegen dem Menschen den Nobelpreis bekommen! Es ist am Tier und am Menschen getestet worden.
https://www.covid19treatmentguidelines.nih.go
Kommentare
Kommentar veröffentlichen